Business
Amarantus Announces Publication of Study on Targeted Delivery of MANF to Brain Areas Associated With Parkinson's Disease
Amarantus Announces Publication of Study on Targeted Delivery of MANF to Brain Areas Associated With Parkinson's Disease.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n - Renishaw plc’s convection-enhanced delivery device results in accurate targeting and distribution of MANF to Parkinson’s disease-associated brain areas -\n - Study confirms the potential of convection-enhanced delivery of MANF as a novel treatment strategy for Parkinson’s disease - - Results support the co-infusion of gadolinium as a proxy measure of MANF distribution in future clinical studies - SAN FRANCISCO and GENEVA, Oct. 06, 2015 (GLOBE NEWSWIRE) --  Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced the publication of a study demonstrating the targeted delivery of mesencephalic-astrocyte-derived neurotrophic factor (MANF) to brain regions associated with Parkinson’s disease in a porcine model. The paper entitled, “Convection-enhanced delivery of MANF – volume of distribution analysis in porcine putamen and substantia nigra1,” from the collaboration with Renishaw plc's (LON:RSW) Neurological Applications Department and the Functional Neurosurgery Research Group at the University of Bristol, was published in the Journal of the Neurological Sciences. The publication reports for the first time the distribution of MANF in putamen and substantia nigra following convection-enhanced delivery (CED) in a large animal model and confirms the potential of targeted infusion of MANF as a novel treatment strategy for PD. The study demonstrates that: (i) MANF can successfully be delivered to the porcine putamen and substantia nigra, the brain areas centrally involved in PD, and (ii) that pharmacologically meaningful volumes of distribution of MANF can be achieved using Renishaw's convection-enhanced delivery device currently in human clinical development. “Our decades-long human experience with convection-enhanced delivery of protein therapeutics taught us that the therapeutic potential of neurotrophic factor treatment of PD is heavily dependent on the ability to accurately and effectively target the affected brain regions,” said Prof. Steven Gill, MB, FRCS, MS, honorary professor of neurosurgery at the University of Bristol. “These published data confirm the translational potential of CED of MANF as a novel treatment strategy in PD....